Drug intelligence / Profile preview

MC-1022

Development stage: Preclinical
Lead developer: Medlab Clinical
Modality: Small Molecules
Administration: Buccal

Overview

MC-1022 is an investigational tetrahydrocannabinol plus cannabidiol oro-buccal spray developed by Medlab Clinical for management of chronic pain. It was included with MC-1019 in a prospectively registered Australian multicentre observational study evaluating the safety, tolerability, and effectiveness of THC-CBD oro-buccal sprays in patients initiating treatment for chronic pain. The publicly available trial record does not disclose the THC:CBD ratio, dose, or a unique marketed brand name for MC-1022. ([anzctr.org.au](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=384495))

Brand names: NanaBidial
Other names: tetrahydrocannabinol + cannabidiolTHC/CBD oro-buccal sprayNanaBidial 18:2

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on MC-1022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MC-1022.

Explore the full profile